• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Belgium In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture - Product Image

Belgium In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

  • Published: December 2011
  • Region: Belgium
  • 205 pages
  • GlobalData

FEATURED COMPANIES

  • Abbott Laboratories
  • bioMerieux S.A.
  • DiaSorin S.p.A
  • Grifols, S.A.
  • Immucor, Inc.
  • Qiagen N.V.
  • MORE

Belgium In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Summary

GlobalData’s new report, “Belgium In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture” provides key market data on the Belgium In Vitro Diagnostics market. The report provides value (USD million) data for each segment and sub-segment within seven market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What is This Report About?
3 In Vitro Diagnostics In Belgium
3.1 In Vitro Diagnostics, Market Segmentation
3.2 In Vitro Diagnostics, Belgium, Overall Revenue ($m), USD Actual, 2003-2017
3.3 In Vitro Diagnostics Market, Belgium, Revenue Mix ($m), 2010
3.4 In Vitro Diagnostics Market, Belgium, Category Contribution (%), 2010
3.5 In Vitro Diagnostics, Belgium, Company share (2009-2010)
4 Clinical Chemistry In Belgium
4.1 Clinical Chemistry, Market Segmentation
4.2 Clinical Chemistry Market, Belgium, Revenue Mix ($m), 2010
4.3 Clinical Chemistry Market, Belgium, Segment Contribution (%), 2010
4.4 Clinical Chemistry Overall Revenue (2003-2017)
4.4.1 Clinical Chemisty Analyzers Revenue (2003-2017)
4.4.2 Urine Analysis Revenue (2003-2017)
4.5 Clinical Chemistry Distribution Share (2009-2010)
4.6 Clinical Chemistry, Belgium, Company share (2009-2010)
5 Genetic Testing In Belgium
5.1 Genetic Testing, Market Segmentation
5.2 Genetic Testing Market, Belgium, Revenue Mix ($m), 2010
5.3 Genetic Testing Market, Belgium, Segment Contribution (%), 2010
5.4 Genetic Testing Overall Revenue (2003-2017)
5.5 Genetic Testing Distribution Share (2009-2010)
5.6 Genetic Testing, Belgium, Company share (2009-2010)
6 Haematology In Belgium
6.1 Haematology, Market Segmentation
6.2 Haematology Market, Belgium, Revenue Mix ($m), 2010
6.3 Haematology Market, Belgium, Segment Contribution (%), 2010
6.4 Haematology Overall Revenue (2003-2017)
6.4.1 Haematology Reagents Revenue (2003-2017)
6.4.2 Immunohaematology Revenue (2003-2017)
6.4.3 Haemostasis Revenue (2003-2017)
6.4.4 Haematology Rapid Tests Revenue (2003-2017)
6.4.5 Haematology Cell Counters Revenue (2003-2017)
6.5 Haematology Distribution Share (2009-2010)
6.6 Haematology, Belgium, Company Share (2009-2010)
7 Histology And Cytology In Belgium
7.1 Histology And Cytology, Market Segmentation
7.2 Histology And Cytology Market, Belgium, Revenue Mix ($m), 2010
7.3 Histology And Cytology Market, Belgium, Segment Contribution (%), 2010
7.4 Histology And Cytology Overall Revenue (2003-2017)
7.5 Histology And Cytology Distribution Share (2009-2010)
7.6 Histology And Cytology, Belgium, Company share (2009-2010)
8 Immuno Chemistry In Belgium
8.1 Immuno Chemistry Market, Belgium, Revenue Mix ($m), 2010
8.2 Immuno Chemistry Market, Belgium, Segment Contribution (%), 2010
8.3 Immuno Chemistry Overall Revenue (2003-2017)
8.3.1 Disease Specific Immunochemistry Revenue (2003-2017)
8.3.2 Drugs of Abuse / Toxicology Revenue (2003-2017)
8.3.3 Endocrinology Tests Revenue (2003-2017)
8.3.4 Therapeutic Drug Monitoring Revenue (2003-2017)
8.3.5 Immunochemistry Analyzers Revenue (2003-2017)
8.4 Immuno Chemistry Distribution Share (2009-2010)
8.5 Immuno Chemistry, Belgium, Company share (2009-2010)
9 Infectious Immunology In Belgium
9.1 Infectious Immunology, Market Segmentation
9.2 Infectious Immunology Market, Belgium, Revenue Mix ($m), 2010
9.3 Infectious Immunology Market, Belgium, Segment Contribution (%), 2010
9.4 Infectious Immunology Overall Revenue (2003-2017)
9.5 Infectious Immunology Distribution Share (2009-2010)
9.6 Infectious Immunology, Belgium, Company share (2009-2010)
10 Microbiology Culture In Belgium
10.1 Microbiology Culture, Market Segmentation
10.2 Microbiology Culture Market, Belgium, Revenue Mix ($m), 2010
10.3 Microbiology Culture Market, Belgium, Segment Contribution (%), 2010
10.4 Microbiology Culture Overall Revenue (2003-2017)
10.4.1 Microbiology Analyzers Revenue (2003-2017)
10.5 Microbiology Culture Distribution Share (2009-2010)
10.6 Microbiology Culture, Belgium, Company share (2009-2010)
11 Overview of Key Companies in Belgium In Vitro Diagnostics Market
11.1 F. Hoffmann-La Roche Ltd.
11.1.1 Company Overview
11.1.2 Share in the Belgium In Vitro Diagnostics Market
11.2 Siemens Healthcare
11.2.1 Company Overview
11.2.2 Share in the Belgium In Vitro Diagnostics Market
11.3 Abbott Laboratories
11.3.1 Company Overview
11.3.2 Share in the Belgium In Vitro Diagnostics Market
11.4 bioMerieux S.A.
11.4.1 Company Overview
11.4.2 Share in the Belgium In Vitro Diagnostics Market
11.5 Ortho-Clinical Diagnostics Inc.
11.5.1 Company Overview
11.5.2 Share in the Belgium In Vitro Diagnostics Market
11.6 Beckman Coulter, Inc.
11.6.1 Company Overview
11.6.2 Share in the Belgium In Vitro Diagnostics Market
11.7 Bio-Rad Laboratories, Inc.
11.7.1 Company Overview
11.8 Sysmex Corporation
11.8.1 Company Overview
11.9 Becton, Dickinson and Company
11.9.1 Company Overview
11.10 Phadia AB
11.10.1 Company Overview
11.11 DiaSorin S.p.A
11.11.1 Company Overview
11.12 Qiagen N.V.
11.12.1 Company Overview
11.13 DIAGNOSTICA STAGO, Inc.
11.13.1 Company Overview
11.14 Gen-Probe Incorporated
11.14.1 Company Overview
11.15 Grifols, S.A.
11.15.1 Company Overview
11.16 Alere Inc.
11.16.1 Company Overview
11.17 Thermo Fisher Scientific Inc.
11.17.1 Company Overview
11.18 HORIBA, Ltd.
11.18.1 Company Overview
11.19 PerkinElmer, Inc.
11.19.1 Company Overview
11.20 Danaher Corporation
11.20.1 Company Overview
11.21 The Elitech Group
11.21.1 Company Overview
11.22 Life Technologies Corporation
11.22.1 Company Overview
11.23 Immucor, Inc.
11.23.1 Company Overview
11.24 Hologic, Inc.
11.24.1 Company Overview
12 In Vitro Diagnostics Market Pipeline Products
12.1 Clinical Chemisty Market Pipeline Products
12.2 Immuno Chemistry Market Pipeline Products
12.3 Haematology Market Pipeline Products
12.4 Infectious Immunology Market Pipeline Products
12.5 Microbiology Culture Market Pipeline Products
12.6 Histology and Cytology Market Pipeline Products
12.7 Genetic Testing Market Pipeline Products
13 Financial Deals Landscape
13.1 Partnerships
13.1.1 Life Technologies Enters Into Co-Development Agreement With GlaxoSmithKline Biologicals
13.1.2 Skyline Diagnostics Enters Into Research Collaboration With Johnson & Johnson Pharmaceutical
13.1.3 BD Diagnostic Enters Into Co-Development Agreement With Diagenode
13.1.4 Trinity Biotech Enters Into Distribution Agreement With A. Menarini Diagnostics
13.1.5 ImaginAb Enters Into Collaboration With Eurogentec
13.1.6 MDxHealth Enters Into Licensing Agreement With Exact Sciences
14 Recent Developments
14.1 Strategy And Business Planning
14.1.1 Nov 16, 2011: DOCS Continues Expansion With Four New Offices In Europe
14.1.2 Mar 18, 2011: Volition Opens Belgian Office And Lab Facilities In Namur, Wallonia
14.2 Government and Public Interest
14.2.1 Jul 26, 2011: Ablynx Receives GLP Certificate For New GLP Unit
14.3 Product News
14.3.1 Mar 22, 2011: DIAsource ImmunoAssays Launches New 25OH Vitamin D Total RIA Test
15 Appendix
15.1 Definitions of Markets Covered in the Report
15.1.1 In Vitro Diagnostics
15.2 Research Methodology
15.3 Secondary Research
15.4 Primary Research
15.5 Models
15.6 Forecasts
15.7 Expert Panels
15.8 GlobalData Consulting
15.9 Currency Conversion
15.10 Contact Us
15.11 Disclaimer

1.1 List of Tables
Table 1: In Vitro Diagnostics, Belgium, Overall Revenue ($m), USD Actual, 2003-2017
Table 2: In Vitro Diagnostics Market, Belgium, Category Contribution (%), 2010
Table 3: In Vitro Diagnostics, Belgium, Cross-Category Analysis, 2003-2017
Table 4: In Vitro Diagnostics, Belgium, Overall Revenue ($m), USD Actual, Historic, 2003-2010
Table 5: In Vitro Diagnostics, Belgium, Overall Revenue ($m), USD Actual, Forecast, 2010-2017
Table 6: In Vitro Diagnostics, Belgium, Company share by Revenue ($m), USD Actual, 2009-2010
Table 7: Clinical Chemistry Market, Belgium, Segment Contribution (%), 2010
Table 8: Clinical Chemistry, Belgium, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 9: Clinical Chemistry, Belgium, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 10: Clinical Chemisty Analyzers, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 11: Clinical Chemisty Analyzers, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 12: Urine Analysis, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 13: Urine Analysis, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 14: Clinical Chemistry, Belgium, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 15: Clinical Chemistry, Belgium, Company share by Revenue ($m), USD Actual 2009-2010
Table 16: Genetic Testing Market, Belgium, Segment Contribution (%), 2010
Table 17: Genetic Testing, Belgium, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 18: Genetic Testing, Belgium, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 19: Genetic Testing, Belgium, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 20: Genetic Testing, Belgium, Company Share by Revenue ($m), USD Actual 2009-2010
Table 21: Haematology Market, Belgium, Segment Contribution (%), 2010
Table 22: Haematology, Belgium, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 23: Haematology, Belgium, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 24: Haematology Reagents, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 25: Haematology Reagents, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 26: Immunohaematology, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 27: Immunohaematology, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 28: Haemostasis, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 29: Haemostasis, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 30: Haematology Rapid Tests, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 31: Haematology Rapid Tests, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 32: Haematology Cell Counters, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 33: Haematology Cell Counters, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 34: Haematology, Belgium, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 35: Haematology, Belgium, Company share by Revenue ($m), USD Actual 2009-2010
Table 36: Histology And Cytology Market, Belgium, Segment Contribution (%), 2010
Table 37: Histology And Cytology, Belgium, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 38: Histology And Cytology, Belgium, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 39: Histology And Cytology, Belgium, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 40: Histology And Cytology, Belgium, Company share by Revenue ($m), USD Actual 2009-2010
Table 41: Immuno Chemistry Market, Belgium, Segment Contribution (%), 2010
Table 42: Immuno Chemistry, Belgium, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 43: Immuno Chemistry, Belgium, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 44: Disease Specific Immunochemistry, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 45: Disease Specific Immunochemistry, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 46: Drugs of Abuse / Toxicology, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 47: Drugs of Abuse / Toxicology, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 48: Endocrinology Tests, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 49: Endocrinology Tests, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 50: Therapeutic Drug Monitoring, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 51: Therapeutic Drug Monitoring, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 52: Immunochemistry Analyzers, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 53: Immunochemistry Analyzers, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 54: Immuno Chemistry, Belgium, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 55: Immuno Chemistry, Belgium, Company share by Revenue ($m), USD Actual 2009-2010
Table 56: Infectious Immunology Market, Belgium, Segment Contribution (%), 2010
Table 57: Infectious Immunology, Belgium, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 58: Infectious Immunology, Belgium, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 59: Infectious Immunology, Belgium, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 60: Infectious Immunology, Belgium, Company share by Revenue ($m), USD Actual 2009-2010
Table 61: Microbiology Culture Market, Belgium, Segment Contribution (%), 2010
Table 62: Microbiology Culture, Belgium, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Table 63: Microbiology Culture, Belgium, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Table 64: Microbiology Analyzers, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Table 65: Microbiology Analyzers, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Table 66: Microbiology Culture, Belgium, Distribution Share by Revenue ($m), USD Actual, 2009-2010
Table 67: Microbiology Culture, Belgium, Company share by Revenue ($m), USD Actual 2009-2010
Table 68: Clinical Chemisty Market Pipeline Products
Table 69: Immuno Chemistry Market Pipeline Products
Table 70: Haematology Market Pipeline Products
Table 71: Infectious Immunology Market Pipeline Products
Table 72: Microbiology Culture Market Pipeline Products
Table 73: Histology and Cytology Market Pipeline Products
Table 74: Genetic Testing Market Pipeline Products
Table 75: Life Technologies Enters Into Co-Development Agreement With GlaxoSmithKline Biologicals
Table 76: Skyline Diagnostics Enters Into Research Collaboration With Johnson & Johnson Pharmaceutical
Table 77: BD Diagnostic Enters Into Co-Development Agreement With Diagenode
Table 78: Trinity Biotech Enters Into Distribution Agreement With A. Menarini Diagnostics
Table 79: ImaginAb Enters Into Collaboration With Eurogentec
Table 80: MDxHealth Enters Into Licensing Agreement With Exact Sciences
Table 81: USD to Local Currency, Belgium, Average Actual Rate 2003-2010

1.2 List of Figures
Figure 1: In Vitro Diagnostics, Market Segmentation
Figure 2: In Vitro Diagnostics, Belgium, Overall Revenue ($m), USD Actual, 2003-2017
Figure 3: In Vitro Diagnostics Market, Belgium, Revenue Mix ($m), 2010
Figure 4: In Vitro Diagnostics Market, Belgium, Category Contribution (%), 2010
Figure 5: In Vitro Diagnostics, Belgium, Cross-Category Analysis, 2003-2017
Figure 6: In Vitro Diagnostics, Belgium, Overall Revenue ($m), USD Actual, Historic, 2003-2010
Figure 7: In Vitro Diagnostics, Belgium, Overall Revenue ($m), USD Actual, Forecast, 2010-2017
Figure 8: In Vitro Diagnostics, Belgium, Company share (%), 2010
Figure 9: Clinical Chemistry, Market Segmentation
Figure 10: Clinical Chemistry Market, Belgium, Revenue Mix ($m), 2010
Figure 11: Clinical Chemistry Market, Belgium, Segment Contribution (%), 2010
Figure 12: Clinical Chemistry, Belgium, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 13: Clinical Chemistry, Belgium, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 14: Clinical Chemisty Analyzers, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 15: Clinical Chemisty Analyzers, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 16: Urine Analysis, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 17: Urine Analysis, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 18: Clinical Chemistry, Belgium, Company share (%), 2010
Figure 19: Genetic Testing, Market Segmentation
Figure 20: Genetic Testing Market, Belgium, Revenue Mix ($m), 2010
Figure 21: Genetic Testing Market, Belgium, Segment Contribution (%), 2010
Figure 22: Genetic Testing, Belgium, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 23: Genetic Testing, Belgium, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 24: Genetic Testing, Belgium, Company Share (%), 2010
Figure 25: Haematology, Market Segmentation
Figure 26: Haematology Market, Belgium, Revenue Mix ($m), 2010
Figure 27: Haematology Market, Belgium, Segment Contribution (%), 2010
Figure 28: Haematology, Belgium, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 29: Haematology, Belgium, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 30: Haematology Reagents, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 31: Haematology Reagents, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 32: Immunohaematology, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 33: Immunohaematology, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 34: Haemostasis, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 35: Haemostasis, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 36: Haematology Rapid Tests, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 37: Haematology Rapid Tests, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 38: Haematology Cell Counters, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 39: Haematology Cell Counters, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 40: Haematology, Belgium, Company Share (%), 2010
Figure 41: Histology And Cytology, Market Segmentation
Figure 42: Histology And Cytology Market, Belgium, Revenue Mix ($m), 2010
Figure 43: Histology And Cytology Market, Belgium, Segment Contribution (%), 2010
Figure 44: Histology And Cytology, Belgium, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 45: Histology And Cytology, Belgium, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 46: Histology And Cytology, Belgium, Company Share (%), 2010
Figure 47: Immuno Chemistry Market, Belgium, Revenue Mix ($m), 2010
Figure 48: Immuno Chemistry Market, Belgium, Segment Contribution (%), 2010
Figure 49: Immuno Chemistry, Belgium, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 50: Immuno Chemistry, Belgium, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 51: Disease Specific Immunochemistry, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 52: Disease Specific Immunochemistry, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 53: Drugs of Abuse / Toxicology, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 54: Drugs of Abuse / Toxicology, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 55: Endocrinology Tests, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 56: Endocrinology Tests, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 57: Therapeutic Drug Monitoring, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 58: Therapeutic Drug Monitoring, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 59: Immunochemistry Analyzers, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 60: Immunochemistry Analyzers, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 61: Immuno Chemistry, Belgium, Company share (%), 2010
Figure 62: Infectious Immunology, Market Segmentation
Figure 63: Infectious Immunology Market, Belgium, Revenue Mix ($m), 2010
Figure 64: Infectious Immunology Market, Belgium, Segment Contribution (%), 2010
Figure 65: Infectious Immunology, Belgium, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 66: Infectious Immunology, Belgium, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 67: Infectious Immunology, Belgium, Company Share (%), 2010
Figure 68: Microbiology Culture, Market Segmentation
Figure 69: Microbiology Culture Market, Belgium, Revenue Mix ($m), 2010
Figure 70: Microbiology Culture Market, Belgium, Segment Contribution (%), 2010
Figure 71: Microbiology Culture, Belgium, Revenue ($m), USD Actual by Segment, Historic, 2003-2010
Figure 72: Microbiology Culture, Belgium, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017
Figure 73: Microbiology Analyzers, Belgium, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010
Figure 74: Microbiology Analyzers, Belgium, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017
Figure 75: Microbiology Culture, Belgium, Company share (%), 2010
Figure 76: F. Hoffmann-La Roche Ltd., Company Share (%),Belgium In Vitro Diagnostics Market, 2010
Figure 77: Siemens Healthcare, Company Share (%),Belgium In Vitro Diagnostics Market, 2010
Figure 78: Abbott Laboratories, Company Share (%),Belgium In Vitro Diagnostics Market, 2010
Figure 79: bioMerieux S.A., Company Share (%),Belgium In Vitro Diagnostics Market, 2010
Figure 80: Ortho-Clinical Diagnostics Inc., Company Share (%),Belgium In Vitro Diagnostics Market, 2010
Figure 81: Beckman Coulter, Inc., Company Share (%),Belgium In Vitro Diagnostics Market, 2010

F. Hoffmann-La Roche Ltd.
Siemens Healthcare
Abbott Laboratories
bioMerieux S.A.
Ortho-Clinical Diagnostics Inc.
Beckman Coulter, Inc.
Bio-Rad Laboratories, Inc.
Sysmex Corporation
Becton, Dickinson and Company
Phadia AB
DiaSorin S.p.A
Qiagen N.V.
DIAGNOSTICA STAGO, Inc.
Gen-Probe Incorporated
Grifols, S.A.
Alere Inc.
Thermo Fisher Scientific Inc.
HORIBA, Ltd.
PerkinElmer, Inc.
Danaher Corporation
The Elitech Group
Life Technologies Corporation
Immucor, Inc.
Hologic, Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos